Related Experiment Videos
Biochemical markers and skeletal metastases
Laurence M Demers1, Luis Costa, Allan Lipton
1Departments of Pathology and Medicine, Penn State University, Hershey, PA 17033, USA. lmd4@psu.edu
Clinical Orthopaedics and Related Research
|November 6, 2003
Summary
Monitoring bone resorption with biochemical markers like telopeptides helps assess cancer patient response to bisphosphonate therapy for metastatic bone disease.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Bisphosphonate therapy is standard for skeletal complications in cancer patients with metastatic bone disease.
- Osteolytic metastases increase bone collagen breakdown products in blood and urine.
- Assessing treatment response is crucial for managing bone metastases.
Purpose of the Study:
- To evaluate the utility of biochemical bone markers in monitoring bisphosphonate therapy response.
- To assess the correlation between bone resorption markers and skeletal involvement in cancer patients.
Main Methods:
- Utilized immunoassays to measure bone collagen breakdown products.
- Focused on carboxy-terminal and amino-terminal telopeptides in blood and urine.
- Correlated marker levels with skeletal involvement and treatment response.
Main Results:
- Biochemical bone markers, specifically telopeptides, are elevated in patients with osteolytic metastases.
- Measurements of these markers correlate with the extent of skeletal involvement.
- These markers aid in monitoring bisphosphonate therapy effectiveness.
Conclusions:
- Biochemical bone markers are valuable adjuncts for managing skeletal metastases in cancer patients.
- Telopeptide measurements facilitate monitoring of bisphosphonate therapy dose and scheduling.
- These markers improve patient care by enabling personalized treatment adjustments.